Clinical Trials Sponsored by Hebei Tumor Hospital

Total 856 results

Hunan Province Tumor Hospital

Completed

Correlation Research of Thioredoxin Reductase in Lung Cancer (TRCRLC)

Non-small Cell Lung Cancer | Benign Neoplasm of Lung

China
Hunan Province Tumor Hospital

Unknown

Clinical Trial of Erlotinib and Pemetrexed for Maintenance Treatment in Lung Adenocarcinoma

Lung Adenocarcinoma
Hunan Province Tumor Hospital

Unknown

Endostar Continued Pumping Into Vein Combining With Gemcitabine-Carboplatin to Treat Non-Small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer

China
Liaoning Tumor Hospital & Institute

Unknown

Bevacizumab Therapy Untreated Unresectable Liver Metastases From Colorectal Cancer

Colorectal Cancer | Liver Metastases

China
Hunan Province Tumor Hospital

Not yet recruiting

Sunvozertinib Plus Anlotinib as 1L Treatment in EGFR Mutant Advanced NSCLC-RW (WUKONG-32-RW)

Non-small Cell Lung Cancer

China
Hunan Province Tumor Hospital

Not yet recruiting

Sunvozertinib Plus Anlotinib as 1L Treatment in EGFR-Sensitive Mutations Combined With Co-Mutations Advanced NSCLC (WUKONG-32)

Non-Small Cell Lung Cancer

China
Hunan Province Tumor Hospital

Not yet recruiting

AK112 Plus Platinum-based Chemotherapy for EGFR/ALK/ROS1 Positve NSCLC (Apple)

Efficacy
Hunan Province Tumor Hospital

Recruiting

A Real-World Study of Treatment Patterns and Effectiveness in MET Mutation-Positive Advanced Lung Cancer

Advanced Lung Cancer

China
Hunan Province Tumor Hospital

Recruiting

A Real-World Study of Atezolizumab in Combination With Platinum-Based Doublet Chemotherapy as Neoadjuvant Therapy for Resectable Stage II-IIIB NSCLC

NSCLC

China
Hunan Province Tumor Hospital

Recruiting

Effect of Time-of-Day (ToD) for Immunochemotherapy on PFS in NSCLC (PACIFIC15)

Non-small Cell Lung Cancer

China
Hunan Province Tumor Hospital

Recruiting

High-dose Furmonertinib for First-line Treatment of EGFR Mutated NSCLC With Central Nervous System (CNS) Metastases

Non-Small Cell Lung Cancer

China
Hunan Province Tumor Hospital

Recruiting

Efficacy and Biomarker Explanation of IBI-323 + Bevacizumab Plus Platinum Based Chemotherapy on ALK-Rearranged NSCLC

Non Small Cell Lung Cancer

China
Hunan Province Tumor Hospital

Recruiting

Atezolizumab Combined With Platinum-based Chemotherapy as Neoadjuvant Therapy for Patients With Resectable Stage II-IIIB

Non Small Cell Lung Cancer

China
Hunan Province Tumor Hospital

Recruiting

Pembrolizumab Plus Bevacizumab and Chemotherapy for ALK-rearranged NSCLC With Persistent 5'ALK (BEYOND)

Lung Adenocarcinoma | ALK Gene Mutation | Immunotherapy

China
Liaoning Tumor Hospital & Institute

Not yet recruiting

Clinical Study of Fulvestrant Combined With Chidamide in the Treatment of Hormone Receptor-positive Advanced Breast Cancer Resistant to CDK4/6 Inhibitors

Breast Cancer
Liaoning Tumor Hospital & Institute

Not yet recruiting

Neoadjuvant Icotinib With Chemotherapy for Epidermal Growth Factor Receptor(EGFR)-Mutated Resectable Lung Adenocarcinoma

NSCLC | EGF-R Positive Non-Small Cell Lung Cancer

China
Hunan Province Tumor Hospital

Recruiting

Efficacy and Biomarker Development for Lung Cancer Treated With Immune Checkpoint Inhibitors (BECOME)

Lung Cancer

China
Hunan Province Tumor Hospital

Recruiting

JS-201 Combined With Lenvatinib in the Treatment of Small-cell Lung Cancer

Small-cell Lung Cancer

China
Hunan Province Tumor Hospital

Recruiting

The Efficacy and Safety of the Bispecific Anti-PD-1/PD-L1 Antibody IBI318 Combined With Lenvatinib in NSCLC.

Non-Small Cell Lung Cancer

China
Hunan Province Tumor Hospital

Recruiting

Survival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced NSCLC

Non-small Cell Lung Cancer

China
Hunan Province Tumor Hospital

Recruiting

Chemotherapy or Chemotherapy Plus PD-1 Antibody in RET Fusion Positive Advanced NSCLC Patitnts: the POSEIDON Trial (POSEIDON)

Non-small Cell Lung Cancer

China
Hunan Province Tumor Hospital

Recruiting

Real World Study on Erlotinib/Gefitinib Combined With Bevacizumab in Advanced Non-aquamous Non-small Cell Lung Cancer

Non Small Cell Lung Cancer

China
Liaoning Tumor Hospital & Institute

Completed

Real-world Study of Inetetamab in HER2-positive Metastatic Breast Cancer

HER2-positive Metastatic Breast Cancer

China
Hunan Province Tumor Hospital

Completed

Association Between the Results of Specific Genetic Tests and the Efficacy of Targeted Therapies in Patients

Non-small Cell Lung Cancer

China
Hunan Province Tumor Hospital

Completed

Antitumor Activity and Safety of BEBT-109, a Novel EGFR Inhibitor, in Previously Treated NSCLC

NSCLC

China
Hunan Province Tumor Hospital

Completed

To Evaluate the Correlation Between the Results of Specific Gene Testing and the Efficacy of Targeted Therapy in Patients With NSCLC

Non Small Cell Lung Cancer

China
Hunan Province Tumor Hospital

Completed

The Prediction Biomarkers of Survival Outcome for Severe Immune-related Hepatitis

Lung Cancer

China
Hunan Province Tumor Hospital

Completed

Ethaselen for the Treatment of Thioredoxin Reductase High Expression Advanced Non-small Cell Lung Cancers

Carcinoma, Non-small Cell Lung

China
Hunan Province Tumor Hospital

Completed

Phase II Study on Sintilimab Combined With Docetaxel for Chemotherapy Failure Advanced NSCLC: the SUCCESS Study (SUCCESS)

Non-small Cell Lung Cancer

China
Hunan Province Tumor Hospital

Completed

Efficacy and Safety of Immunotherapy in Non-small Cell Lung Cancer With Uncommon Histological Type (Esporta)

Uncommon Pathological Types of Lung Cancer

China
Liaoning Tumor Hospital & Institute

Unknown

Irinotecan for Advanced and Metastatic Breast Cancer

Breast Cancer

China
Hunan Province Tumor Hospital

Completed

Early Warning Study of Serum Thioredoixn Reductase Activity in Excised Non-small Cell Lung Cancers (EWSOTRILC)

Non-small Cell Lung Cancer Stage I | Non-small Cell Lung Cancer Stage IIIA | Non-small Cell Lung Cancer Stage II

China
Jilin Provincial Tumor Hospital

Unknown

Feasibility Study of SOL (S-1,Oral Leucovorin,and Oxaliplatin) in Patients With Advanced Gastric Cancer

Gastric Cancer

China
Hebei Province Veterans Hospital

Completed

Dance/Movement Therapy for Bone Mineral Density in Schizophrenia

Schizophrenia

China
Hebei Yanda Ludaopei Hospital

Completed

LILRB4 STAR-T Cells in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia

Relapsed/Refractory Acute Myeloid Leukemia

China
Hebei Senlang Biotechnology Inc., Ltd.
Hebei Yanda Ludaopei Hospital

Recruiting

Safety and Efficacy of CD19/CD22 Dual Targeted CAR-T Cell Therapy in R/R B-Cell Acute Lymphoblastic Leukemia

CD19+ and CD 22+ B-ALL

China
Hebei Senlang Biotechnology Inc., Ltd.
Hebei Yanda Ludaopei Hospital

Active, not recruiting

Senl_1904A and Senl_1904B Chimeric Antigen Receptor （CAR） T-Cell in the Treatment of r/ r Acute B Lymphocytic Leukemia

Acute Lymphocytic Leukemia

China
Hebei Yanda Ludaopei Hospital

Not yet recruiting

Study on Intelligent Nutrition Support Therapy for Hematopoietic Stem Cell Transplantation Recipients

Nutrition Aspect of Cancer | Stem Cell Transplant Complications
Hebei Yanda Ludaopei Hospital

Unknown

A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma

Relapsed or Refractory Multiple Myeloma

China
Cancer Institute and Hospital, Chinese Academy...
Jilin Provincial Tumor Hospital; Hebei Medical University Fourth Hospital; Liaoning... and other collaborators

Unknown

A Multicenter, Randomized, Case-control Study of Unilateral vs Bilateral Neck Dissection for cN0 Supraglottic Laryngeal Cancer

Laryngeal Neoplasms | Malignant Neoplasm of Supraglottis Primary | Neck Dislocation

China
Hebei Senlang Biotechnology Inc., Ltd.
Hebei Yanda Ludaopei Hospital

Unknown

Study Evaluating Safety and Efficacy of CAR-T Cells Targeting CD123 in Patients With Acute Myelocytic Leukemia

Acute Myelocytic Leukemia

China
Hebei Senlang Biotechnology Inc., Ltd.
Hebei Medical University Fourth Hospital

Recruiting

Multicenter Clinical Study on the Safety and Effectiveness of CAR-T in the Treatment of Relapsed/Refractory Plasma Cell Tumors

Plasma Cell Tumors

China
Hebei Senlang Biotechnology Inc., Ltd.
Hebei Medical University Fourth Hospital

Recruiting

Clinical Trial of CAR-T in the Treatment of Relapsed and Refractory Hematopoietic and Lymphoid Tissue Tumors in Children

Lymphoma | Leukemia

China
Fudan University
Anyang Tumor Hospital

Not yet recruiting

Everolimus Combined With PD-1 in Advanced Colorectal Cancer Patients

Colon Cancer

China
Hebei Medical University Fourth Hospital

Recruiting

Clinical Study of Breast Conserving Surgery Combined With Intraoperative Radiotherapy for Early Breast Cancer

Breast Cancer | HER2-negative Breast Cancer

China
Hebei Medical University Third Hospital

Recruiting

Evaluation of AKR1B10 as a New Marker for Interventional Therapy of Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
Hebei Medical University Fourth Hospital

Not yet recruiting

Liposomal Irinotecan and Leucovorin/5-fluorouracil Plus Bevacizumab in Metastatic Colorectal Cancer

Colorectal Cancer
Hebei Medical University Third Hospital

Recruiting

Mechanism of Cardiac and Cerebral Function Injury Caused by Intraoperative Limb Ischemia-reperfusion

Ischemic Reperfusion Injury

China
Hebei Medical University Fourth Hospital

Not yet recruiting

Efficacy and Safety of Dalpiciclib in Hormone Receptor-positive Advanced Breast Cancer

Breast Cancer
Hebei Medical University Fourth Hospital

Not yet recruiting

Dalpiciclib Combined With Letrozole in Neoadjuvant Treatment of Stage Ⅱ-Ⅲ HR-positive/HER2-negative Breast Cancer

Solid Tumor

3

Subscribe